Crocs, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Crocs, Inc. trades at $131.94 (market cap $6.31B), while State Street SPDR S&P Biotech ETF trades at $158.55. Which is the better fit depends on your goals.
| CROX | XBI | |
|---|---|---|
Market Cap | $6.31B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $141.19 | $164.28 |
52-Week Low | $73.39 | $86.92 |
Enterprise Value | $7.83B | — |
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $138.19, up 1.15% today, near its 52-week high. The stock shows bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $4.55 versus $4.35 expected. Revenue trends are stable around $4B annually, though 2025 net income was negative due to high taxes. Analysts maintain a buy-heavy consensus with a $140.43 price target.
Outlook is positive with robust profitability margins and valuation support, but risks include tax scrutiny from recent Malta office news and HEYDUDE brand weakness. The stock offers growth potential if execution improves, yet investors face volatility from guidance misses and competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →